No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC By Ogkologos - March 3, 2026 40 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SONIA study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR COVID-19 Is Decimating Nursing Homes, So GreaterGood Has Donated Masks To... May 8, 2020 Neoadjuvant Niraparib Demonstrates Promising Antitumour Activity and Safety in Patients with... August 10, 2022 How I Rebuilt My Self-Image After a Laryngectomy: A Cancer Survivor’s... April 20, 2023 Why investing in cancer research is good for the economy July 1, 2022 Load more HOT NEWS FDA Approves Imlunestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast... ctDNA-Guided Therapy with Pertuzumab plus Trastuzumab for HER2-Amplified mCRC More Than One in 10 Patients With Lung Cancer Do Not... Pembrolizumab Plus Axitinib Outperforms Sunitinib in Patients with Metastatic Renal Cell...
